Bristol Myers Squibb Company BMY and partner Acceleron Pharma Inc. XLRN announced that the FDA has approved a label expansion of Reblozyl (luspatercept-aamt). The drug has been approved for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback